For laboratory research use only. Not for human consumption.
Talk to our research support team: 512-998-2437
For laboratory research use only. Not for human consumption.
Talk to our research support team: 512-998-2437
Price range: $33.00 through $310.00
These products are for laboratory research only and not intended for medical use. They are not FDA-approved to diagnose, treat, cure, or prevent any disease. By purchasing, you certify they will be used solely for research and not for human or animal consumption.
Research Use Only
All research peptides supplied by OPTMZ Peptides are intended strictly for laboratory research applications and are not designed for medical use. These materials are not approved by the U.S. Food and Drug Administration (FDA) to diagnose, treat, cure, or prevent any disease. By purchasing, the buyer confirms use strictly for scientific research purposes and not for human or animal consumption.
Product Overview
CJC-1295 (without DAC), commonly associated with Modified GRF (1-29), is a synthetic growth hormone-releasing hormone analog designed for experimental study of GHRH receptor signaling without the albumin-binding Drug Affinity Complex found in CJC-1295 with DAC.
It is a 29-amino-acid peptide analog investigated in endocrine and pituitary research, including GHRH receptor activation, growth hormone signaling, IGF-1-associated pathways, and peptide structure-function studies.
Unlike CJC-1295 with DAC, the non-DAC form does not contain the albumin-binding DAC moiety, making it structurally and pharmacologically distinct.
Research Use Only
All research peptides supplied by OPTMZ Peptides are intended strictly for laboratory research applications and are not designed for medical use. These materials are not approved by the U.S. Food and Drug Administration (FDA) to diagnose, treat, cure, or prevent any disease. By purchasing, the buyer confirms use strictly for scientific research purposes and not for human or animal consumption.
Product Overview
CJC-1295 (without DAC), commonly associated with Modified GRF (1-29), is a synthetic growth hormone-releasing hormone analog designed for experimental study of GHRH receptor signaling without the albumin-binding Drug Affinity Complex found in CJC-1295 with DAC.
It is a 29-amino-acid peptide analog investigated in endocrine and pituitary research, including GHRH receptor activation, growth hormone signaling, IGF-1-associated pathways, and peptide structure-function studies.
Unlike CJC-1295 with DAC, the non-DAC form does not contain the albumin-binding DAC moiety, making it structurally and pharmacologically distinct.
The purity, identity, measured content, and CAS number above come directly from the independent laboratory report for the submitted OPTMZ sample.
PubChem lists CJC-1295 without DAC as C₁₅₂H₂₅₂N₄₄O₄₂.
Each tested batch of CJC-1295 (without DAC) undergoes analytical evaluation to verify chromatographic purity, identity, peptide content, and analytical consistency.
For the submitted OPTMZ Peptides sample, Krause Analytical reported:
The laboratory states that the data presented are from the analyzed sample and meet its internal quality-assurance criteria unless otherwise flagged.
Page 2 of the report includes both the chromatogram and a direct mass-spectrum/reference-spectrum comparison for the CJC-1295 sample.
Note: This COA does not report endotoxin testing, so I would not state that this specific lot was endotoxin tested.
CJC-1295 (without DAC) should be handled by qualified professionals in controlled laboratory environments. Appropriate storage conditions should be maintained to preserve peptide stability and structural integrity.
Avoid unnecessary exposure to heat, moisture, light, and repeated temperature fluctuations. Experimental preparation, storage, and handling should follow validated laboratory procedures appropriate to the intended research application.
CJC-1295 (without DAC) is investigated primarily as a GHRH analog for experimental study of the growth hormone-releasing hormone receptor and downstream endocrine signaling.
Research areas include:
The non-DAC form is structurally related to Modified GRF (1-29), a stabilized GHRH-derived peptide designed to retain GHRH receptor activity while avoiding the albumin-binding DAC modification.
This distinction is important because much of the published human literature on CJC-1295 specifically concerns the DAC-containing long-acting form, not necessarily the non-DAC peptide. Published CJC-1295 studies therefore should not automatically be used to make pharmacokinetic claims about CJC-1295 without DAC.
CJC-1295 (without DAC) is relevant to controlled laboratory investigations involving GHRH receptor biology, pituitary signaling, growth-hormone-associated pathways, endocrine cell signaling, and peptide structure-function relationships.
Because it lacks the Drug Affinity Complex, it is especially relevant to comparative research examining DAC versus non-DAC GHRH analogs and how albumin-binding modifications alter peptide persistence and pharmacology.
For laboratory research use only. Intended strictly for in vitro and controlled experimental research applications.
All products currently listed on this site are for research purposes ONLY.
The purity, identity, measured content, and CAS number above come directly from the independent laboratory report for the submitted OPTMZ sample.
PubChem lists CJC-1295 without DAC as C₁₅₂H₂₅₂N₄₄O₄₂.
Each tested batch of CJC-1295 (without DAC) undergoes analytical evaluation to verify chromatographic purity, identity, peptide content, and analytical consistency.
For the submitted OPTMZ Peptides sample, Krause Analytical reported:
The laboratory states that the data presented are from the analyzed sample and meet its internal quality-assurance criteria unless otherwise flagged.
Page 2 of the report includes both the chromatogram and a direct mass-spectrum/reference-spectrum comparison for the CJC-1295 sample.
Note: This COA does not report endotoxin testing, so I would not state that this specific lot was endotoxin tested.
CJC-1295 (without DAC) should be handled by qualified professionals in controlled laboratory environments. Appropriate storage conditions should be maintained to preserve peptide stability and structural integrity.
Avoid unnecessary exposure to heat, moisture, light, and repeated temperature fluctuations. Experimental preparation, storage, and handling should follow validated laboratory procedures appropriate to the intended research application.
CJC-1295 (without DAC) is investigated primarily as a GHRH analog for experimental study of the growth hormone-releasing hormone receptor and downstream endocrine signaling.
Research areas include:
The non-DAC form is structurally related to Modified GRF (1-29), a stabilized GHRH-derived peptide designed to retain GHRH receptor activity while avoiding the albumin-binding DAC modification.
This distinction is important because much of the published human literature on CJC-1295 specifically concerns the DAC-containing long-acting form, not necessarily the non-DAC peptide. Published CJC-1295 studies therefore should not automatically be used to make pharmacokinetic claims about CJC-1295 without DAC.
CJC-1295 (without DAC) is relevant to controlled laboratory investigations involving GHRH receptor biology, pituitary signaling, growth-hormone-associated pathways, endocrine cell signaling, and peptide structure-function relationships.
Because it lacks the Drug Affinity Complex, it is especially relevant to comparative research examining DAC versus non-DAC GHRH analogs and how albumin-binding modifications alter peptide persistence and pharmacology.
For laboratory research use only. Intended strictly for in vitro and controlled experimental research applications.
All products currently listed on this site are for research purposes ONLY.
| Pcs | Single Vial, Pack of 10 |
|---|---|
| Strength | 5mg |
Short-Acting GHRH Analog / Modified GRF Research Peptide
Endocrinology; Peptide Biology; GHRH/GH Axis Research; Pituitary Biology; Molecular Signaling; Peptide Pharmacology
Growth Hormone-Releasing Hormone Receptor (GHRHR) Unlike CJC-1295 with DAC, there is no albumin-binding DAC target interaction associated with this form.
Preclinical / Experimental Research There is established biological knowledge concerning GHRH receptor signaling and modified GHRH peptides, but published human CJC-1295 studies predominantly concern the DAC-containing molecule rather than the non-DAC form. I would therefore not classify CJC-1295 without DAC as “Clinical Research” based solely on CJC-1295 DAC studies.
CJC-1295 without DAC is a 29-amino-acid modified GHRH-derived peptide lacking the Drug Affinity Complex present in long-acting CJC-1295. Its structure incorporates substitutions intended to improve stability relative to native GHRH while preserving activity at the growth hormone-releasing hormone receptor.
Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH₂ One-letter shorthand: Y-D-A-A-I-F-T-Q-S-Y-R-K-V-L-A-Q-L-S-A-R-K-L-L-Q-D-I-L-S-R-NH₂ A commercial peptide reference lists this sequence for CJC-1295 without DAC.
GHRH receptor signaling studies
Growth hormone secretion pathway research
Pituitary-cell biology
Somatotroph signaling studies
GH/IGF-1 axis research
Peptide stability research
GHRH analog structure-function studies
Comparative DAC versus non-DAC research
Endocrine signaling studies
Modified GRF research
Relevant experimental systems include:
GHRH receptor-expressing cell systems
Pituitary cell models
Somatotroph-associated experimental systems
GH secretion assays
Endocrine signaling models
Modified GHRH biochemical systems
Peptide receptor-binding models
Comparative peptide-stability systems
Important: Controlled human CJC-1295 studies primarily concern the DAC-containing form, so those systems should not automatically be represented as evidence for CJC-1295 without DAC.
HPLC-UV chromatographic purity analysis
LC-MS identity confirmation
Mass-spectrum/reference-spectrum matching
GHRH receptor activation assays
GH secretion assays
Receptor-binding assays
cAMP signaling assays
Pituitary-cell response assays
Peptide stability assays
Comparative pharmacology assays
For the actual OPTMZ product, the COA specifically documents HPLC-UV-MS analysis and mass-spectrum/reference-spectrum matching.
Chromatographic purity
Peptide identity
Peptide content
GHRHR activation
Intracellular cAMP signaling
Growth hormone release
Pituitary-cell response
Peptide stability
Receptor interaction
Endocrine signaling responses
For the actual OPTMZ lot, the directly measured analytical endpoints were purity, identity, and CJC-1295 content.
Independent analytical testing of OPTMZ Peptides CJC-1295 No DAC 2 mg, lab sample 200510, by Krause Analytical reported:
Chromatographic Purity: 99.31%
CJC-1295 Content: 2.04 mg
Label Claim: 2 mg
Percent of Label: 101.9%
Identity: Confirmed
CAS Number: 863288-34-0
Analysis Method: HPLC-UV-MS
Lab Number: 200510
Project: 145030
Date Received: January 29, 2026
Report Issued: February 9, 2026
The report includes a chromatogram and mass-spectrum/reference-spectrum comparison on page 2.
Restricted Access · Research Use Only
Independently lab tested, every batch
COAs published and searchable by batch number
Policy version 2026-05-14-ruo-v1.0
Reviews
There are no reviews yet.